Urelumab
This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Name
- Urelumab
- Accession Number
- DB12077
- Description
Urelumab has been used in trials studying the treatment of Leukemia, Multiple Myeloma, Malignant Tumors, and Cancer - Solid Tumors and B-Cell Non-Hodgkin's Lymphoma. Urelumab is a fully human antibody that targets CD137. The antibody product was developed using Medarex's UltiMAb(R) technology and was the first UltiMAb- derived antibody in clinical development by Bristol-Myers Squibb under the December 2003 agreement with Medarex.
- Type
- Biotech
- Groups
- Investigational
- Biologic Classification
- Protein Based Therapies
Monoclonal antibody (mAb) - Protein Chemical Formula
- Not Available
- Protein Average Weight
- Not Available
- Sequences
- Not Available
- Synonyms
- Not Available
- External IDs
- BMS 663513
- BMS-663513
- BMS-66513
Pharmacology
- Indication
- Not Available
- Contraindications & Blackbox Warnings
Learn about our commercial Contraindications & Blackbox Warnings data.
Learn More- Pharmacodynamics
- Not Available
- Mechanism of action
Target Actions Organism UTumor necrosis factor receptor superfamily member 9 Not Available Humans - Absorption
- Not Available
- Volume of distribution
- Not Available
- Protein binding
- Not Available
- Metabolism
- Not Available
- Route of elimination
- Not Available
- Half-life
- Not Available
- Clearance
- Not Available
- Adverse Effects
Learn about our commercial Adverse Effects data.
Learn More- Toxicity
- Not Available
- Affected organisms
- Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Unlock Additional DataAbciximab The risk or severity of adverse effects can be increased when Abciximab is combined with Urelumab. Adalimumab The risk or severity of adverse effects can be increased when Adalimumab is combined with Urelumab. Alemtuzumab The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Urelumab. Alirocumab The risk or severity of adverse effects can be increased when Alirocumab is combined with Urelumab. Ansuvimab The risk or severity of adverse effects can be increased when Urelumab is combined with Ansuvimab. Anthrax immune globulin human The risk or severity of adverse effects can be increased when Anthrax immune globulin human is combined with Urelumab. Antilymphocyte immunoglobulin (horse) The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin (horse) is combined with Urelumab. Antithymocyte immunoglobulin (rabbit) The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Urelumab. Asfotase alfa The risk or severity of adverse effects can be increased when Asfotase alfa is combined with Urelumab. Atezolizumab The risk or severity of adverse effects can be increased when Atezolizumab is combined with Urelumab. Additional Data Available- Extended DescriptionExtended DescriptionAvailable for Purchase
Extended description of the mechanism of action and particular properties of each drug interaction.
Learn more - SeveritySeverityAvailable for Purchase
A severity rating for each drug interaction, from minor to major.
Learn more - Evidence LevelEvidence LevelAvailable for Purchase
A rating for the strength of the evidence supporting each drug interaction.
Learn more - ActionActionAvailable for Purchase
An effect category for each drug interaction. Know how this interaction affects the subject drug.
Learn more
- Food Interactions
- Not Available
Categories
- Drug Categories
- Chemical TaxonomyProvided by Classyfire
- Description
- Not Available
- Kingdom
- Organic Compounds
- Super Class
- Organic Acids
- Class
- Carboxylic Acids and Derivatives
- Sub Class
- Amino Acids, Peptides, and Analogues
- Direct Parent
- Peptides
- Alternative Parents
- Not Available
- Substituents
- Not Available
- Molecular Framework
- Not Available
- External Descriptors
- Not Available
Chemical Identifiers
- UNII
- 230902QLLC
- CAS number
- 934823-49-1
References
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 2 Completed Treatment Melanoma 1 2 Recruiting Treatment Cancer, Bladder / Transitional Cell Carcinoma 1 2 Withdrawn Treatment Leukemias 1 1 Active Not Recruiting Treatment Glioblastomas / Gliosarcoma / Recurrent Brain Neoplasm 1 1 Active Not Recruiting Treatment Malignancies 1 1 Completed Treatment B-Cell Malignancies 1 1 Completed Treatment Cancer - Solid Tumors and B-Cell Non-Hodgkin's Lymphoma 1 1 Completed Treatment Colorectal Cancers / Head and Neck Carcinoma 1 1 Completed Treatment Multiple Myeloma (MM) 1 1 Completed Treatment Neoplasms Malignant 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
Targets
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- General Function
- Tumor necrosis factor-activated receptor activity
- Specific Function
- Receptor for TNFSF9/4-1BBL. Possibly active during T cell activation.
- Gene Name
- TNFRSF9
- Uniprot ID
- Q07011
- Uniprot Name
- Tumor necrosis factor receptor superfamily member 9
- Molecular Weight
- 27898.6 Da
Drug created on October 20, 2016 15:18 / Updated on June 12, 2020 10:53